HUTCHMED (China) Limited

HCM | NASDAQ

Price Alert Chart Builder DCF Calculator

$14.48

+$0.81 (+5.93%)

At close: Sep 21, 2026, 4:00 PM ET

$14.25

-$0.23 (-1.56%)

Pre-market: Sep 22, 2026, 4:29 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+5.93%

(1D)

Rating

Updated: Sep 9, 2026

33.7

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $2.53B

1D Range

14.06 14.55

52W Range

9.77 16.99

Valuation (TTM)

PE 155.70

PB 2.00

EV/EBITDA -60.65

Valuation (NTM)

Forward PE 21.68

Forward PEG 2.51

Price Target $22.78

Cash Flow

FCF Yield 0.4%

SBC Adj. FCF Yield -0.1%

SBC Impact -126.3%

Margins

Gross Margin 0.2%

Operating Margin -6.3%

FCF Margin 1.8%

Growth (CAGR)

Revenue 3Y | 5Y -10.2% | 14.5%

Dil EPS 3Y | 5Y 20.2% | 376.1%

FCF 3Y | 5Y 60.8% | 66.7%

Returns

ROA 1.0%

ROE 1.4%

ROIC -2.1%

Financial Health

Net Cash

$1.28B

Current Ratio 5.64

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related di...

Sector Healthcare

Industry Drug Manufacturers - Specialty & Generic

Employees 1,796

IPO Date Mar 15, 2016

Website www.hutch-med.com

Fiscal Year January - December

Full Company Profile

Latest News

1 day ago · marketbeat.com

Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data

Lexicon Pharmaceuticals NASDAQ: LXRX said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027.

4 days ago · gurufocus.com

Workday Named a Leader in Inaugural 2026 Gartner® Magic Quadrant™ for Workforce Management Technology

Workday Named a Leader in Inaugural 2026 GartnerÂ Magic Quadrantâ¢ for Workforce Management TechnologyPR NewswirePLEASANTON, Calif., Sept. 17, 2026Workday Uni

19 days ago · marketbeat.com

HUTCHMED Lands GSK Deal Worth Up to $1.3B for KRAS-EGFR Cancer Therapy

HUTCHMED NASDAQ: HCM said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC. The transaction has a total potential value of approximately $1.3 billion, including a $110 million upfront payment, according to Acting Chief Executive Officer and Chief Financial Officer Johnny Cheng.

19 days ago · seekingalpha.com

HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 Transcript

23 days ago · globenewswire.com

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China

Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting Findings build on the established success of the global SAFFRON and China SACHI trials, extending the clinical value of the all-oral combination into the first-line setting

26 days ago · globenewswire.com

HUTCHMED Announces NMPA Approval for ATLED® (Fanregratinib) for the Treatment of Patients with FGFR2-Fusion/Rearrangement Intrahepatic Cholangiocarcinoma

Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China Novel, highly potent oral selective FGFR 1/2/3 inhibitor approved for patients with advanced FGFR2-altered intrahepatic cholangiocarcinoma in China

1 month ago · seekingalpha.com

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets

Lexicon Pharmaceuticals (LXRX) is nearing multiple potential value-transforming events for sotagliflozin, and the shares have been strong since my last update. Sotagliflozin, targeting HCM and T1D, is the primary value driver; the pivotal SONATA-HCM Phase III readout is expected in 2027, and an NDA re-filing for T1D before year-end. Regulatory and commercialization risks arguably outweigh clinical risk, especially for T1D, as the company would have to commit considerable resources to commercialization to maximize the value of sotagliflozin.

1 month ago · proactiveinvestors.co.uk

HUTCHMED shares rise as lung cancer drug trial hits key targets

Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung cancer drug savolitinib. The Phase III SAFFRON study tested savolitinib, sold as Orpathys, in combination with AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) Tagrisso in patients with a form of non-small cell lung cancer whose disease had worsened despite treatment.